

Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER Bezlotoxumab (ZINPLAVA) Infusion

Page 1 of 2

ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE

Patient Identification

Height: _____cm Weight: kg Allergies: Diagnosis Code: Treatment Start Date: Patient to follow up with provider on date:

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

This plan will expire after 365 days at which time a new order will need to be placed

GUIDELINES FOR ORDERING

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. Restricted to ambulatory use in patients who have failed or do not quality for FMT, in consultation with ID. (OHSU only)
- 3. Bezlotoxumab is not indicated for the treatment of Clostridium difficile infection (CDI). It should only be used in conjunction with antibacterial drug treatment of CDI.
- 4. Heart failure has been reported at a higher rate in patients treated with bezlotoxumab (compared to placebo), primarily occurring in patients with underlying heart failure. Additionally, a higher mortality rate due to cardiac failure, infection, and respiratory failure was observed in patients with a history of heart failure who received bezlotoxumab (compared to those who received placebo). In patients with a history of heart failure, bezlotoxumab use should be reserved for situations when the benefits outweigh risks.

NURSING ORDERS:

1. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes

MEDICATIONS

☑ bezlotoxumab (ZINPLAVA) 10 mg/kg in sodium chloride 0.9%, intravenous, ONCE, over 60 minutes

HYPERSENSITIVITY MEDICATIONS:

- 1. NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Bezlotoxumab (ZINPLAVA) Infusion

ACCOUNT NO. MED. REC. NO. NAME

BIRTHDATE

Page 2 of 2	Patient Identification	
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE. By signing below, I represent the following: am responsible for the care of the patient (who is identified at the top of this form); hold an active, unrestricted license to practice medicine in: □ Oregon □ (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);		
Provider signature: Date/Time:		
Printed Name:	Phone:	Fax:
Please check the appropriate box for the patien	t's preferred clinic	location:
☐ Hillsboro Medical Center Infusion Services 364 SE 8th Ave, Medical Plaza Suite 108B Hillsboro, OR 97123 Phone number: (503) 681-4124 Fax number: (503) 681-4120	□ Adventist Health Portland Infusion Services 10123 SE Market St Portland, OR 97216 Phone number: (503) 261-6631 Fax number: (503) 261-6756	
☐ Mid-Columbia Medical Center Celilo Cancer Center 1800 E 19th St The Dalles, OR 97058 Phone number: (541) 296-7585 Fax number: (541) 296-7610		